Reliability of adverse symptom event reporting by clinicians

Quality of Life Research

Volumn 21, Issue 7, 2012, Pages 1159-1164

  Atkinson, Thomas M ^a   Li, Yuelin ^a   Coffey, Charles W ^b   Sit, Laura ^a   Shaw, Mary ^a   Lavene, Dawn ^a   Bennett, Antonia V ^a   Fruscione, Mike ^a   Rogak, Lauren ^a   Hay, Jennifer ^a   Gönen, Mithat ^a   Schrag, Deborah ^c   Basch, Ethan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Drug toxicity; Reproducibility of results; Risk assessment; Statistical data interpretation

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG TOXICITY; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; NEOPLASM; PHYSICIAN; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; STANDARD;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIANS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84867071185     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-011-0031-4     Document Type: Article

References (23)

1. NCI: National Cancer Institute. (2001). Cancer therapy evaluation program. NCI guidelines - Expedited adverse event reporting requirements for NCI investigational agents. Bethesda: National Cancer Institute.
2. Basch, E., Iasonos, A., Barz, A., et al. (2007). Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. Journal of Clinical Oncology, 25, 5374-5380.
3. Basch, E. (2010). The missing voice of patients in drug-safety reporting. New England Journal of Medicine, 362, 865-869.
4. Basch, E., Jia, X., Heller, G., et al. (2009). Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes. Journal of the National Cancer Institute, 101, 1624-1632.
5. Belknap, S. M., Georgopoulos, C. H., West, D. P., et al. (2010). Quality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs. Clinical Pharmacology and Therapeutics, 88, 231-236.
6. Ahmad, S. R. (2003). Adverse drug event monitoring at the Food and Drug Administration. Journal of General Internal Medicine, 18, 57-60.
7. Trotti, A., Colevas, A. D., Setser, A., et al. (2007). Patientreported outcomes and the evolution of adverse event reporting in oncology. Journal of Clinical Oncology, 25, 5121-5127.
8. Trotti, A., Colevas, A. D., Setser, A., et al. (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse events of cancer treatment. Seminars in Radiation Oncology, 13, 176-181.
9. Basch, E., Iasonos, A., McDonough, T., et al. (2006). Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. The Lancet Oncology, 7, 903-909.
10. Bruner, D. W., Bryan, C. J., Aaronson, N., et al. (2007). Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. Journal of Clinical Oncology, 25, 5051-5057.
11. US Food and Drug Administration. (2009). Guidance for industry. Patient-reported outcome measures: Use in medical development to support labeling claims. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInfor mation/Guidances/UCM193282.pdf. Accessed 9 Dec 2010
12. Uebersax, J. S. (1987). Diversity of decision-making models and the measurement of interrater agreement. Psychological Bulletin, 101, 140-146.
13. Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86, 420-428.
14. Rosner, B. (2005). Fundamentals of biostatistics. Belmont, CA: Duxbury Press.
15. McGill, R., Tukey, J. W., & Larsen, W. A. (1978). Variation of box plots. The American Statistician, 32, 12-16.
16. Zegers, M., de Bruijne, M. C., Wagner, C., et al. (2010). The inter-rater agreement of retrospective assessments of adverse events does not improve with two reviewers per patient record. Journal of Clinical Epidemiology, 63, 94-102.
17. Weingart, S. N., Gandhi, T. K., Seger, A. C., et al. (2005). Patient-reported medication symptoms in primary care. Archives of Internal Medicine, 165, 234-240.
18. Berry, D. L., Moinpour, C. M., Jiang, C. S., et al. (2006). Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of Clinical Oncology, 24, 2828-2835.
19. Pakhomov, S., Jacobsen, S. J., Chute, C. G., et al. (2008). Agreement between patient-reported symptoms and their documentation in the medical record. The American Journal of Managed Care, 14, 530-539.
20. Hahn, E. A., Cella, D., Chassany, O., et al. (2007). Precision of health-related quality-of-life data compared with other clinical measures. Mayo Clinic Proceedings, 82, 1244-1254.
21. Ioannidis, J. P., Evans, S. J., Gøtzsche, P. C., et al. (2004). Better reporting of harms in randomized trials: An extension of the CONSORT statement. Annals of Internal Medicine, 141, 781-788.
22. Institute of Medicine, National Academy of Sciences. (2006). The future of drug safety: Promoting and protecting the health of the public. Washington, DC: National Academies Press.
23. Kirkova, J., Davis, M. P., Walsh, D., et al. (2006). Cancer symptom assessment instruments: A systematic review. Journal of Clinical Oncology, 24, 1459-1473.